Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Semmelweis University
• Treatments: Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

• Chronic central serous chorioretinopathy (CSCR) with persistent subretinal fluid on OCT for more than 3 months after initial presentation .

• Written informed consent

Exclusion Criteria:

• Persons with impaired decision-making ability.

• Pregnant women or who are actively trying to conceive.

• Additional eye disease affecting the macula or posterior retina.

• Creatinine clearance < 50 ml/min

• Hyperkalemia > 5 mmol/l

• Serum creatinine > 2 mg/dl in men or > 1.8 mg/dl in women

• Treatment with potassium sparing agents or potassium

• Treatment with any other drugs known to cause interaction with eplerenone

• Microalbuminuria in patients with type 2 diabetes